Testosterone
Established medicineAlso known as 17beta-hydroxy-4-androsten-3-one, AndroGel, Androderm, Aveed+42 more
17beta-hydroxy-4-androsten-3-one, AndroGel, Androderm, Aveed, Axiron, Azmiro, Delatest, Delatestadiol, Delatestryl, Dep Androgyn, Depo-Testadiol, Depo-Testosterone, Depotest, Depotestogen, Duo-Cyp, Dura-Dumone, Duratest, Duratestrin, Estra-Testrin, Everone, Fortesta, Histerone, Jatenzo, Kyzatrex, Meditest, Natesto, Striant, Synovex H, Testamone-100, Testim, Testoderm, Testolin, Testopel, Testosterone Cypionate, Testosterone Enanthate, Testosterone Propionate, Testro, Testro AQ, Tlando, Undecatrex, Vogelxo, Xyosted, Testosteron, Testosterona, Testostérone, Testosteronum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Testosterone therapy may lead to CVD risk in postmenopausal women
Low testosterone may make sugar far more harmful to your liver
Testosterone for Menopause May Carry Heart Risks
What to Say to Patients Taking Testosterone to Get ‘Jacked’
Label change: TESTOSTERONE (ANDA209390)
Neurology of Androgens and Androgenic Supplements.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The Journal of clinical endocrinology and metabolism5
- Frontiers in endocrinology4
- Andrology3
- Nutrients3
- International journal of molecular sciences2
- The Journal of clinical investigation2
- den Heijer M3
- Bubley GJ2
- Clarke SA2
- Corona G2
- Vanderschueren D2
- Wang C2
- Wiepjes CM2
- Abbara A1
- Baylor College of Medicine2
- Center of Expertise on Gender Dysphoria2
- Imperial College London2
- Medical School2
- School of Medical Sciences2
- School of Medicine2
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 13 of the same disease areas as Testosterone in the shared literature.
Studied across 17 of the same disease areas as Testosterone in the shared literature.
Studied across 8 of the same disease areas as Testosterone in the shared literature.
Studied across 12 of the same disease areas as Testosterone in the shared literature.
Studied across 6 of the same disease areas as Testosterone in the shared literature.
Studied across 9 of the same disease areas as Testosterone in the shared literature.
Studied across 11 of the same disease areas as Testosterone in the shared literature.
Studied across 11 of the same disease areas as Testosterone in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.